From Name:
From Email:
To Name:
To Email:

Optional Message:


New immunotherapy could be 'game changer' in NSCLC

from Medscape Medical News

A new immunotherapy, MPDL3280A (under development by Genentech), has shown impressive results in a small group of patients with heavily pretreated nonsmall-cell lung cancer who were taking part in a phase 1 clinical trial. All but 1 of the 53 NSCLC patients responded, and the responses are "outstandingly durable," Jean-Charles Soria, M.D., from the Institut Gustave Roussy in Villejuif, France, said. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063